Safe the Date - SURV1VE-Trial Investigator Meeting on April 27, 2025 6-8 PM at PAS 2025

Event Name: SURV1VE-Trial Meeting

Date and Time: Sunday April 27, 2025, 6:00 PM - 8:00 PM

Location:  Hilton Hawaiian Village: South Pacific I (Mid-Pacific Conference Center)

Session ID: 1967879

SURV1VE-Trial Investigator Meeting Overview: Advancing Newborn CPR

Cardiopulmonary resuscitation (CPR) at birth is an essential intervention for newborns, both full-term and preterm, with 0.1% to 15% requiring chest compressions (CC) immediately after delivery. Despite this critical intervention, the outcomes for these infants remain troubling. Mortality rates for newborns who undergo CPR are approximately 41%, and neurological morbidity is alarmingly high. Over half (57%) of resuscitated infants experience hypoxic-ischemic encephalopathy and seizures, both of which are linked to long-term neurological deficits. Unlike adults, for whom cardiac arrest is typically due to underlying heart conditions, the primary cause in newborns is asphyxia, making their resuscitation needs unique.

Current CPR Protocols and Their Limitations

The traditional approach to neonatal CPR relies on a 3:1 compression-to-ventilation (C:V) ratio, a model originally adapted from adult resuscitation guidelines. However, this ratio is based largely on adult data, which may not effectively address the distinct physiological needs of newborns experiencing asphyxia-related cardiac arrest. The 3:1 C:V ratio has been effective in sustaining life but falls short in significantly improving long-term neurological outcomes in newborns. This gap has led researchers and clinicians to investigate alternative CPR methods that may better support both immediate survival and neurological health in infants.

A New Approach: Chest Compressions During Sustained Inflation (CC+SI)

A promising alternative method currently under study is chest compressions combined with sustained inflation (CC+SI). Unlike the traditional 3:1 C:V ratio, CC+SI involves continuous chest compressions alongside sustained airway pressure, enhancing both ventilation and circulation. Initial studies on CC+SI have shown promising results, indicating quicker return of spontaneous circulation (ROSC) and improved survival rates. Pilot trials have demonstrated that CC+SI could offer significant benefits over the 3:1 Cmethod, particularly in achieving faster ROSC—a critical factor in reducing the risk of neurological damage and improving survival rates.

However, while early findings are encouraging, the data from these preliminary studies are not yet sufficient to establish CC+SI as the standard for neonatal CPR. To address this, the SURV1VE trial aims to conduct a large, multi-center study to rigorously evaluate the impact of CC+SI on reducing mortality and improving neurological outcomes compared to the traditional 3:1 C:V method. By confirming or refining these early findings, the SURV1VE trial has the potential to set a new standard in neonatal resuscitation.

The SURV1VE-Trial Meeting: Shaping the Future of Newborn Resuscitation

The upcoming SURV1VE-trial meeting is a critical milestone in advancing neonatal CPR research. The meeting will bring together experts, researchers, and clinicians to discuss the trial’s design and methodologies, as well as to gather feedback on its objectives and potential impact. We encourage all Pediatric Academic Societies (PAS) participants to join, as their insights and expertise will be invaluable in refining the trial framework and optimizing outcome measurement.

The SURV1VE-trial meeting also aims to expand the trial’s reach by inviting new sites to join this groundbreaking research effort. For healthcare institutions and researchers interested in advancing neonatal resuscitation, participating in the SURV1VE trial presents a unique opportunity to contribute to the development of potentially life-saving protocols. Joining the SURV1VE trial community means not only advancing scientific knowledge but also making a direct impact on improving outcomes for the most vulnerable patients—newborns in critical need of resuscitation.

Join the SURV1VE-Trial Initiative

Whether you are a seasoned neonatal researcher or a clinician passionate about improving newborn outcomes, we welcome your participation in the SURV1VE-trial meeting. Your feedback, ideas, and expertise are essential in shaping a trial that could redefine the standards of neonatal resuscitation worldwide. Together, we can work towards better survival rates and neurological outcomes for infants, giving them a healthier start to life.

To learn more about the SURV1VE trial and the upcoming meeting, please reach out to the organizers at schmolze@ualberta.ca or visit our official website. Let’s make a difference in neonatal care—join us in the SURV1VE trial effort!